PDCD1 and melanoma: Additionally, another randomized phase III trial in melanoma is open exploring the value of adding T-VEC to the programmed cell death protein 1 (PD-1) inhibitor, pembrolizumab, for treatment of unresected melanoma (NCT02263508).